FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy

What's GSK's return on marketing?

Tools

If you're wondering how GlaxoSmithKline's sales-and-marketing team is doing, we might have the answer. Blogger Jim Edwards looks at GSK's yield on its marketing dollars and finds that they're "just about treading water." The revenue yield and gross profit yield on every dollar the company spent on selling, general, and administrative expenses was flat last quarter, down from 1 percent and 7 percent respectively in the first quarter. "The overall trend seems to be down," Edwards notes. Then he offers some cold comfort: After looking at these numbers for one drugmaker after another, he says, he knows that GSK isn't alone in seeing its marketing ROI lose steam.

- see the post at NRx

Related Articles:
Layoffs, consolidation at GSK Consumer Health
Chemists laid off at GlaxoSmithKline
GSK outlines plans to become more ‘biotech-like'

More stories about Drug Marketing   GlaxoSmithKline   Sales and marketing  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 64 + 0?
To combat spam, please solve the math question above.